Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
| ▸ | PRKDC | P78527 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 8/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123495 | 0.85 | SRC (0.52) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1319216 | 0.84 | PIK3CD (0.48) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1318894 | 0.81 | SRC (0.62) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12436039 | 0.81 | SRC (0.65) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29390295 | 0.81 | SRC (0.65) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19731412 | 0.80 | BTK (0.61) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19731411 | 0.79 | BTK (0.60) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29589300 | 0.79 | BTK (0.60) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1320349 | 0.79 | SRC (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1318810 | 0.79 | SRC (0.79) | BTKPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8697709-B2 | Fused ring heteroaryl kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011047384-A2 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | BTK 4429/4885PIK3CD 2956/4885PIK3CA 3212/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | BTK 315/4885PIK3CD 276/4885PIK3CA 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.